Our work has demonstrated that the concentrations of the pro-inflammatory mediators, anaphaylatoxin C3a and C5a, were significantly increased in critical COVID-19 patients relative to mild and non-infected groups. This evidence concerns the gene C5AR1 and COVID-19.